Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC).

24 Jun 2013

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

18 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

ARIAD Pharmaceuticals, Inc. today announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors.

11 Jun 2013

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include depression, fatigue, nausea and change of appearance.

11 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

A research team led by the Duke-NUS Graduate Medical School in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia, making it possible to develop drugs that may extend the survival of these patients.

4 Jun 2013

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

Cancer vaccine company DCPrime today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia.

28 May 2013

Liposomal anthracycline-based chemotherapy effective for children with leukemia: Study

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology.

24 May 2013

Caltech biologists show that microRNA-146a protects stem cells during inflammation

When infections occur in the body, stem cells in the blood often jump into action by multiplying and differentiating into mature immune cells that can fight off illness. But repeated infections and inflammation can deplete these cell populations, potentially leading to the development of serious blood conditions such as cancer.

22 May 2013

New computational method may help track tumor progression, risk of relapse

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual cells. These technologies have led to new challenges, however, as scientists now struggle with how to make sense of the resulting trove of data. Now a solution may be at hand.

20 May 2013

BioLineRx signs ATM sales agency agreement with Stifel

BioLineRx Ltd., a biopharmaceutical development company, announced today that it has entered into an at-the-market sales agency agreement with Stifel.

18 May 2013

Viewpoints: When a doctor should keep quiet; 2 views of hospital pricing; Stem cell 'snake oil'

In medical school, we were taught not to withhold information from our patients or to be "paternal" in making decisions for them. We internalized the idea that fully informed patients are better equipped to make treatment decisions.

17 May 2013

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Two seminars and seven poster sessions, Beckman Coulter will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.

From Beckman Coulter Life Sciences - Flow Cytometry 16 May 2013

Secure cloud-based computing system to access, analyze human genomic cancer information

The University of Chicago launched the first secure cloud-based computing system that enables researchers to access and analyze human genomic cancer information without the costly and cumbersome infrastructure normally needed to download and store massive amounts of data.

16 May 2013

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).

14 May 2013

Study results suggest that CNL and aCML patients could be treated with FDA-approved drugs

Patients with two forms of leukemia, who currently have no viable treatment options, may benefit from existing drugs developed for different types of cancer, according to a study conducted by researchers at the Knight Cancer Institute at Oregon Health & Science University.

13 May 2013

Entremed reports patent issuance for its lead drug candidate ENMD-2076

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.

7 May 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

3 May 2013